文献速递MDS 与骨髓增殖性肿瘤

识别骨髓纤维化临床试验中的疾病修饰潜力

Identifying disease-modifying potential in myelofibrosis clinical trials.
PubMed 文献 · Blood · 2024-01-01

该文讨论骨髓纤维化临床试验中替代终点的问题,指出JAK抑制剂仅改善症状和脾大而有限影响疾病自然史,建议以分子学突变负荷下降等疾病负担指标替代现有终点,并需重新分析已有数据以确定最有用的替代终点。

要点

  • JAK抑制剂对骨髓纤维化症状负担和脾大有特定作用,但对疾病自然史影响有限。
  • 作者认为应摆脱专为测量JAK抑制剂获益而设计的终点,以加速新药临床开发。
  • 作者提出以分子终点确定的突变负荷下降等疾病负担指标替代现有终点。

核心结论

  • 作者认为骨髓纤维化新药临床开发应摆脱专为测量JAK抑制剂获益而设计的终点,以加速开发。
  • 作者提出以分子终点确定的突变负荷下降等疾病负担指标替代现有终点。
  • 需仔细重新分析现有数据和进行中的试验,以确定未来骨髓纤维化试验最有用的替代终点。

研究设计与样本

  • 原文为观点性文章,未报告系统检索范围或样本量。

主要发现

  • JAK抑制剂对骨髓纤维化有减少症状负担和脾大的特定作用,但对疾病自然史影响有限。
  • 自十余年前芦可替尼引入以来,骨髓纤维化临床试验仅有适度渐进成功,未出现改变疾病自然史的重大飞跃。
  • 已确立的替代终点例子包括慢性髓性白血病和急性白血病的微小残留病监测,以及淋巴瘤的代谢反应评估。

关键数值与推荐

  • 原文未报告具体数值或推荐条款。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The ultimate goal of bringing most new drugs to the clinic in hematologic malignancy is to improve overall survival. However, the use of surrogate end points for overall survival is increasingly considered standard practice, because a well validated surrogate end point can accelerate the outcome assessment and facilitate better clinical trial design. Established examples include monitoring minimal residual disease in chronic myeloid leukemia and acute leukemia, and metabolic response assessment in lymphoma. However, what happens when a clinical trial end point that is not a good surrogate for disease-modifying potential becomes ingrained as an expected outcome, and new agents are expected or required to meet this end point to demonstrate "efficacy"? Janus kinase (JAK) inhibitors for myelofibrosis (MF) have a specific impact on reducing symptom burden and splenomegaly but limited impact on the natural history of the disease. Since the introduction of ruxolitinib more than a decade ago there has been modest incremental success in clinical trials for MF but no major leap forward to alter the natural history of the disease. We argue that the clinical development of novel agents for MF will be accelerated by moving away from using end points that are specifically tailored to measure the beneficial effects of JAK inhibitors. We propose that specific measures of relevant disease burden, such as reduction in mutation burden as determined by molecular end points, should replace established end points. Careful reanalysis of existing data and trials in progress is needed to identify the most useful surrogate end points for future MF trials and better serve patient interest.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ross DM, Lane SW, Harrison CN, et al. Identifying disease-modifying potential in myelofibrosis clinical trials. Blood. 2024. PMID: 39172741. doi:10.1182/blood.2024024220

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。